XML 49 R32.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Licenses, Asset Acquisitions and Contingent Consideration (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract] |
Schedule of IPR&D Expense | The Company recorded the following IPR&D expense on the consolidated statements of operations and comprehensive loss (in thousands):
| Year Ended December 31,
| 2024 |  | 2023 |  | 2022
Seralutinib | $ | — |  |  | $ | 10,000 |  |  | $ | — |
Terminated programs | — |  |  | — |  |  | 65 |
Total in process research and development | $ | — |  |  | $ | 10,000 |  |  | $ | 65 |

X
- Definition In process research and development expenses. + References No definition available. + Details
Name: | goss_InProcessResearchAndDevelopmentExpensesTableTextBlock
Namespace Prefix: | goss_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_BusinessCombinationAndAssetAcquisitionAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration